Pages that link to "Q36943252"
Jump to navigation
Jump to search
The following pages link to Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity (Q36943252):
Displaying 50 items.
- Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal (Q21033747) (← links)
- Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax (Q24273364) (← links)
- Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control (Q24656072) (← links)
- Malaria and helminth interactions in humans: an epidemiological viewpoint (Q24677835) (← links)
- A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum (Q24814432) (← links)
- Can follicular helper T cells be targeted to improve vaccine efficacy? (Q26753848) (← links)
- Discovery of a novel and conserved Plasmodium falciparum exported protein that is important for adhesion of PfEMP1 at the surface of infected erythrocytes (Q27974160) (← links)
- A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum (Q27974528) (← links)
- Malaria Parasites: The Great Escape (Q28080325) (← links)
- Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans (Q30492536) (← links)
- Clag9 is not essential for PfEMP1 surface expression in non-cytoadherent Plasmodium falciparum parasites with a chromosome 9 deletion. (Q31044131) (← links)
- Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. (Q33305467) (← links)
- Helminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area (Q33319239) (← links)
- Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses (Q33333604) (← links)
- Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses. (Q33385010) (← links)
- Identification of a vaccine candidate antigen, PfMAg-1, from Plasmodium falciparum with monoclonal antibody M26-32. (Q33506430) (← links)
- Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens (Q33509282) (← links)
- Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children (Q33512533) (← links)
- Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms (Q33533310) (← links)
- IL4 gene polymorphism and previous malaria experiences manipulate anti-Plasmodium falciparum antibody isotype profiles in complicated and uncomplicated malaria (Q33562843) (← links)
- Isotypic analysis of Plasmodium falciparum-specific antibodies and their relation to protection in Madagascar (Q33612549) (← links)
- Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort (Q33621604) (← links)
- Analysis of Inhibitory Epitopes in thePlasmodium falciparumRhoptry Protein RAP-1 Including Identification of a Second Inhibitory Epitope (Q33749504) (← links)
- Impact of schistosome infection on Plasmodium falciparum Malariometric indices and immune correlates in school age children in Burma Valley, Zimbabwe (Q33749755) (← links)
- Antigenicity of recombinant proteins derived from rhoptry-associated protein 1 of Plasmodium falciparum (Q33751469) (← links)
- Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigens (Q33756304) (← links)
- Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. (Q33866742) (← links)
- Interethnic differences in antigen-presenting cell activation and TLR responses in Malian children during Plasmodium falciparum malaria (Q33869738) (← links)
- Allelic diversity and antibody recognition of Plasmodium falciparum merozoite surface protein 1 during hypoendemic malaria transmission in the Brazilian amazon region. (Q34002481) (← links)
- High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria (Q34003525) (← links)
- Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam (Q34008262) (← links)
- Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity (Q34008755) (← links)
- Assessment of the effect of Schistosoma haematobium co infection on malaria parasites and immune responses in rural populations in Gabon: study protocol (Q34028797) (← links)
- Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1*/DQB1* in malaria exposed individuals from the Brazilian Amazon. (Q34078790) (← links)
- Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro model (Q34123317) (← links)
- Associations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infection (Q34145697) (← links)
- Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen (Q34194609) (← links)
- Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure (Q34257253) (← links)
- Increased frequency of malaria attacks in subjects co-infected by intestinal worms and Plasmodium falciparum malaria (Q34272993) (← links)
- Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka. (Q34301073) (← links)
- Anti-malarial market and policy surveys in sub-Saharan Africa (Q34407223) (← links)
- Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria (Q34515219) (← links)
- Analysis of human antibodies to erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum (Q34537136) (← links)
- Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites (Q34540211) (← links)
- Antibody-Mediated and Cellular Immune Responses Induced in Naive Volunteers by Vaccination with Long Synthetic Peptides Derived from the Plasmodium vivax Circumsporozoite Protein (Q34546220) (← links)
- Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children (Q34704130) (← links)
- Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens (Q34778078) (← links)
- Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria (Q34855814) (← links)
- Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children (Q35016669) (← links)
- Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains (Q35060442) (← links)